What is Damora Therapeutics, Inc. (DMRA) stock price today?

Damora Therapeutics, Inc. (DMRA) is currently trading at $21.08, up 2.53% today.

What is DMRA P/E ratio?

Damora Therapeutics, Inc.'s P/E ratio is -0.17. This is below the market average, suggesting the stock may be undervalued relative to earnings.

What is DMRA return on equity (ROE)?

Damora Therapeutics, Inc.'s return on equity (ROE) is -82.56%, indicating how efficiently the company generates profit from shareholders' equity. This is below the typical market average of 12-15%.

What is Damora Therapeutics, Inc.'s market cap?

Damora Therapeutics, Inc. has a market capitalization of $1.30B.

NASDAQ · Medical - Pharmaceuticals

Damora Therapeutics, Inc. (DMRA) Stock

$21.08 +2.53% NASDAQ: DMRA Healthcare

Valuation

Metric	Value
Price	$21.08
Market Cap	$1.30B
P/E Ratio	-0.17
P/B Ratio	2.54
P/S Ratio	0.00
EPS (TTM)	$-2.44
52-Week High	$38.33
52-Week Low	$3.50
Dividend Yield	0.00%

Financials & Margins

Metric	Value
ROE	-82.56%
ROA	-48.35%
ROCE	-52.44%
Gross Margin	0.00%
Operating Margin	0.00%
Net Margin	0.00%
Debt/Equity	0.00
Current Ratio	12.98

Annual Financials (USD)

Metric	2021	2022	2023	2024	2025
Revenue	$0	$0	$0	$0	$0
Operating Profit	$-52.0M	$-61.0M	$-36.0M	$-17.0M	$-211.0M
Net Profit	$-52.0M	$-62.0M	$-38.0M	$-21.0M	$-210.0M
EPS	$-51.22	$-60.63	$-36.08	$-18.53	$-152.99
Op Margin	—	—	—	—	—

Balance Sheet (USD)

Metric	2021	2022	2023	2024	2025
Total Assets	$122.0M	$73.0M	$38.0M	$17.0M	$261.0M
Total Liabilities	$5.0M	$11.0M	$6.0M	$3.0M	$20.0M
Cash	$63.0M	$33.0M	$21.0M	$14.0M	$258.0M
Borrowings	$1.0M	$1.0M	$0	$1.0M	$0

Latest News

Damora Therapeutics Completes Redomestication to Cayman Islands MT Newswires · Jul 17, 2026 Damora Announces Redomestication from Delaware to Cayman Islands GlobeNewswire · Jul 17, 2026 Damora Therapeutics Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4) GlobeNewswire · Jul 1, 2026 HC Wainwright Initiates Damora Therapeutics at Buy With $45 Price Target MT Newswires · Jun 11, 2026 TD Cowen Initiates Damora Therapeutics at Buy MT Newswires · Jun 8, 2026

Cash Flow (USD)

Metric	2021	2022	2023	2024	2025
Operating Cash Flow	$-52.0M	$-43.0M	$-37.0M	$-19.0M	$-7.0M
Investing Cash Flow	$-48.0M	$12.0M	$22.0M	$12.0M	$-17.0M
Financing Cash Flow	$0	$0	$0	$0	$0
Net Cash Flow	$-101.0M	$-30.0M	$-11.0M	$-7.0M	$243.0M
Free Cash Flow	$-53.0M	$-43.0M	$-37.0M	$-19.0M	$-7.0M

Valuation & Return Ratios

Metric	Value
PEG Ratio	0.00
EV / EBITDA	-2.93
FCF Yield	-3.17%
Quick Ratio	19.73
Interest Coverage	0.00
Return 1Y	651.91%
Return 3Y	-51.43%
Return 5Y	-74.06%

Ownership

Insiders Held7.62%

Institutions Held94.05%

Institutions Float Held101.81%

Institutional Holder	Shares	Report Date
FMR, LLC	9,045,481	2026-03-31
Fairmount Funds Management LLC	8,713,000	2026-03-31
Avoro Capital Advisors LLC	3,783,000	2026-03-31
Venrock Adviser, LLC	3,603,595	2026-03-31
FCPM III Services B.V.	2,441,000	2026-03-31

Peer Comparison

Ticker	Price	Change	P/E	Market Cap	Div Yield
COAGHemab Therapeutics Holdings, Inc. Common Stock	$31.62	+2.36%	-24.14	$1.48B	0.00%
GERNGeron Corporation	$1.23	+0.41%	-12.04	$785.86M	0.00%
GMABGenmab A/S	$29.00	-2.62%	21.45	$17.80B	0.00%
INCYIncyte Corporation	$113.14	+0.35%	15.15	$22.93B	0.00%
IRONDisc Medicine, Inc.	$62.16	+2.29%	-9.92	$2.39B	0.00%

About Damora Therapeutics, Inc.

Damora Therapeutics, Inc. is led by CEO Jennifer A. Jarrett, employs 7 people, headquartered in US, publicly traded since 2026.

Damora Therapeutics, Inc. (DMRA) stock trades at $21.08 with a market capitalization of $1.30B. The stock is valued at a price-to-earnings (P/E) ratio of -0.17, price-to-book of 2.54, price-to-sales of 0.00. Over the past 52 weeks the stock has ranged between $3.50 and $38.33, and currently trades 45.0% below its 52-week high.

On profitability, Damora Therapeutics, Inc. generates a return on equity (ROE) of -82.56%, return on capital employed of -52.44%, an operating margin of 0.00%, a net profit margin of 0.00%.

Related Healthcare Stocks

LLY Eli Lilly and Company $1179.27 +0.83% JNJ Johnson & Johnson $261.44 +1.93% ABBV AbbVie Inc. $276.47 +1.49% MRK Merck & Company, Inc. Common Stock (new) $145.60 +2.26% UNH UnitedHealth Group Incorporated Common Stock (DE) $379.30 +2.25% NVS Novartis AG $143.75 +0.45% AZN AstraZeneca PLC $159.31 +0.33% TMO Thermo Fisher Scientific Inc $658.02 +0.93% AMGN Amgen Inc. $414.87 +1.82% GILD Gilead Sciences, Inc. $151.17 +2.77% ABT Abbott Laboratories $99.60 +1.13% NVO Novo Nordisk A/S $38.67 +1.27%

Screens featuring this stock

High ROE Healthcare Stocks Low P/E Healthcare Stocks High Net Margin Healthcare Stocks Dividend Healthcare Stocks Low Debt Healthcare Stocks Nasdaq High ROE Stocks All stock screens

Run Stock Screener Investing Guides